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Chloride (Cl−) homeostasis is an essential process involved in neuronal signalling and cell survival. Inadequate regulation
of intracellular Cl− interferes with synaptic signalling and is implicated in several neurological diseases. The main inhibitory
neurotransmitter of the central nervous system is 𝛾-aminobutyric acid (GABA). GABA hyperpolarises the membrane potential
by activating Cl− permeable GABAA receptor channels (GABAAR). This process is reliant on Cl
− extruder K+-Cl− cotransporter
2 (KCC2), which generates the neuron’s inward, hyperpolarising Cl− gradient. KCC2 is encoded by the fifth member of the
solute carrier 12 family (SLC12A5) and has remained a poorly understood component in the development and severity of many
neurological diseases for many years. Recent advancements in next-generation sequencing and specific gene targeting, however,
have indicated that loss of KCC2 activity is involved in a number of diseases including epilepsy and schizophrenia. It has also
been implicated in neuropathic pain following spinal cord injury. Any variant of SLC12A5 that negatively regulates the transporter’s
expression may, therefore, be implicated in neurological disease. A recent whole exome study has discovered several causative
mutations in patients with epilepsy. Here, we discuss the implications of KCC2 in neurological disease and consider the evolving
evidence for KCC2’s potential as a therapeutic target.
1. Introduction
Chloride (Cl−) is an abundant anion involved in a variety of
physiological processes including gene regulation [1, 2], pH
maintenance [3], and control of cell volume [4]. Primarily
important in the neuron, Cl− plays a crucial role in signalling
within the central nervous system (CNS). Healthy brain func-
tion requires the correct balance of neuronal excitation and
inhibition to determine the firing of action potentials. Action
potentials enable rapid propagation of signals. Imbalance of
inhibitory and excitatory signals can lead to the development
of neurological insults [5–7].
The main inhibitory neurotransmitter, 𝛾-aminobutyric
acid (GABA), binds to the ionotropic receptor GABA type A
channel (GABAAR) [8–10]. GABA’s role in signalling depends
on the intracellular Cl− ([Cl−]i) concentration, which deter-
mines the reversal potential for GABAA currents (𝐸GABA).
𝐸GABA lies close to the resting membrane potential (RMP)
[11, 12]. Both 𝐸GABA and RMP vary between cell types and
compartments. The depolarising or hyperpolarising effect of
GABAergic signalling is dependent on the relative RMP and
𝐸GABA. When [Cl
−]i is high,𝐸GABA is less negative and GABA
stimulation results in depolarisation; when it is low, 𝐸GABA
is more negative and GABA stimulation is hyperpolarising
[13, 14]. In healthy adult neuron’s [Cl−]i is usually maintained
at a low concentration, enabling inhibitory, hyperpolarising
GABAergic signalling [15]. This constitutes the main role
of GABA in CNS neurotransmission; its potential dysfunc-
tion in neurological disease due to dysregulated cellular
Cl− levels is, therefore, of significant interest. Depolarising
GABA potentials, in contrast, are commonly observed in
immature and peripheral neurons [16]. Finally, in addition
to GABA’s role in hyperpolarisation, it is able to act in a
further inhibitory capacity via the mechanism of “shunting
inhibition.” This process involves increased membrane con-
ductance as a result of GABA stimulation “short circuiting”
nearby excitatory potentials without producing a significant
change in membrane potential.
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Figure 1: GABAA signalling shis from depolarizing to hyperpolarising responses during development. In immature pyramidal cells,
GABAAR-mediated Cl− currents are outward and depolarising because the relative ratio of NKCC1 to KCC2 activity is high. In mature
neurons, increased KCC2 activity gives rise to inward GABAA-mediated Cl
− currents that hyperpolarize the membrane potential.
Neuronal [Cl−]i is regulated by the Na
+-K+-2Cl− cotrans-
porter 1 (NKCC1) and the K+-Cl− cotransporter 2 (KCC2)
[17]. Using the Na+ gradient generated by Na/K/ATPase,
NKCC1 drives Cl− into the cell; KCC2, in contrast, is the
main Cl− extruder in mature neurons [18]. During devel-
opment, NKCC1 and KCC2 expression patterns change. In
the immature CNS, NKCC1 dominates resulting in high
[Cl−]i. As maturation proceeds, KCC2 expression increases
whilst NKCC1 levels fall (Figure 1) [19, 20]. Mature neurons,
therefore, have low [Cl−]i causing a shift in 𝐸GABA from
depolarising to hyperpolarising [19, 20]. Thus, KCC2 is a
crucial regulator of GABA-mediated hyperpolarisation: an
essential component of synaptic inhibition within the adult
brain (Figure 2).
Loss of KCC2 activity orchestrates a depolarising shift in
𝐸GABA and is implicated in cortical development systems such
as neuro- and synaptogenesis [12, 21]. The fundamental role
that KCC2 downregulation plays in these processes suggests a
causal link between Cl− homeostasis and the pathogenesis of
neurodevelopmental disorders [22, 23]. Although categorised
differently, neurodevelopmental disorders including autism
and schizophrenia display phenotypic similarities, most
notably high copy number variation [24]. These attributes
suggest a genetic link between these diseases.
Excitatory and inhibitory imbalance is implicated in the
onset of epilepsy. Biopsies of epileptic tissue have identi-
fied excitatory GABA activity in response to loss of KCC2
expression and subsequent [Cl−]i increase [25–27]. Similarly,
in Huntington’s disease positive rat models, upregulation of
NKCC1 and loss of KCC2 caused GABA mediated stimula-
tion to switch from an inhibitory to excitatory response [28].
Collectively, these studies suggest that researching expression
patterns of KCC2 may further our understanding of the
aetiology of these diseases.
The aim of this review is to evaluate the role of KCC2 in
various pathological conditions. Consideration will first be
given to the structure of KCC2; how this affects its function
and expression is a key component to understanding its role
in disease. Attention will also be given to specific diseases
in which KCC2 dysfunction is implicated. Finally, KCC2
will be discussed as a pharmaceutical target for neurological
diseases.
2. Structure and Diversity of the Cl−
Cotransporter KCC2
The KCC2 Cl− cotransporter is transcribed from the fifth
member of the solute carrier 12 (SLC12A5) gene family.
During alternative splicing, SLC12A5 produces two isoforms:
KCC2a and KCC2b [29]. The KCC2a transcript is commonly
expressed in the spinal cord between embryonic day (E) 14
and postnatal day (P) 60, whilst KCC2b is greatly upregulated
in the hippocampus and the neocortex between E17-P14
[29]. As development progresses, KCC2a expression falls
whilst KCC2b is upregulated in the mature CNS. KCC2a
is, therefore, the favoured isoform in the immature brain
but is eventually dominated by KCC2b in adulthood [30].
Structural differences between these isoforms are localised to
the N-terminus where they possess a unique 40 amino acid
structure. Despite this, their ion transport activity is almost
identical [31]. For the purposes of this review, KCC2 denotes
KCC2b.
Although KCC2 is one of the most heavily researched
transporters within the CNS, limitations in X-ray analysis
BioMed Research International 3
Epileptic neuronHealthy neuron
GABA
−40
−60
−80
M
em
br
an
e
Po
te
nt
ia
l (
m
V
)
Depolarizing GABA 
GABA−40
−60
−80
Hyperpolarizing GABA
KCC2
GABA
KCC2
GABA
NKCC1NKCC1
＋
+
＋
+
．；
+
2＃Ｆ
−
[＃Ｆ
−
]） low
＃Ｆ
− ＃Ｆ
−
＃Ｆ
−
＇！＂！！２ ＇！＂！！２
＋
+
．；
+
2＃Ｆ
−
[＃Ｆ
−
]） high
＋
+
＃Ｆ
−
％＇！＂！
％＇！＂！
M
em
br
an
e
Po
te
nt
ia
l (
m
V
)
Figure 2:NeuronalCl− volume is reciprocally regulated viaNKCC1 andKCC2. In healthymature neurons, [Cl−]i is lowdue to the opposing
activity profiles of NKCC1 and KCC2. This promotes GABAAR-mediated hyperpolarization, which is critical for the proper balance of
excitation-inhibition in neuronal circuits (left panel). In neurons implicated inmultiple neuropsychiatric conditions driven by hyperexcitable
circuits (e.g., seizures, neuropathic pain, spasticity, schizophrenia, and others), [Cl−]i are elevated due to increased NKCC1 activity, and/or
decreased KCC2 activity, promoting GABAAR-mediated membrane depolarization and excitation (right panel).
have led to poor understanding of its structure and functional
mechanisms. Hydropathy blot analysis suggests that KCC2
contains 12 transmembrane domains anchored by intracel-
lular N- and C-termini [32]. Precisely half of the protein
is intracellular and is the target for a number of kinases
and a single phosphatase (Figure 3). Studies have begun
to uncover an integral role of the C-terminus in KCC2
activity [33]. For example, posttranslational modifications -
phosphorylation and/or glycosylation have been associated
with the extrusive qualities displayed by KCC2 [34–36].
During development, KCC2 assembly becomes more com-
plex, with immature brains displaying a higher monomeric
count whilst oligomerisation correlates with maturation [37].
More recently, Agez and colleagues showed that KCC2
exists in a monomeric and dimeric state in solution [38].
The same group also noted that peptide C-terminal tag-
ging of KCC2 caused detrimental functional changes and
inactivation when expressed in HEK293 cells [38]. Their
findings suggest a crucial role of the KCC2 C-terminus in its
activity.
Whilst these findings provide insight into the functional
significance of KCC2 structure, they fail to show this effect
in a neuronal setting. HEK293 are an embryonic kidney cell
line commonly used in the analysis of ion homeostasis. Both
KCC2 isoforms are predominantly expressed in neurons of
the brain and spinal cord, organs with several physiological
and functional differences to the kidney. These differences
are evident in the findings of Uravov and colleagues who
noted that inhibition of KCC2 mRNA expression differs
between neuronal and nonneuronal cells. KCC2 mRNA
expression is mediated by RE-1 silencing transcription factor
in nonneuronal cells, which represses the SLC12A5 gene
[39]. In neurons, however, the transcription factor early
growth response 4 (Erg4) is developmentally upregulated,
stimulating an increase in KCC2.This indicates fundamental
differences in KCC2 expression between cell types [40]. Fur-
ther research in CNS specific cell types (e.g. neuroblastoma
or primary neurons) is required to determine the therapeutic
implications of KCC2 expression.
In animalmodels of traumatic and ischaemic brain injury,
KCC2 is reportedly downregulated at both the protein and
mRNA levels [41–43]. Six hours after transient forebrain
ischaemia, the KCC2 peptide became more abundant in the
dendritic regions of pyramidal cells in the cornu Ammonis
1 (CA1) region of the hippocampus, which displayed no
evidence of damage. Over an extended time period (48 h
after stroke induction), the same cells began to degenerate
in a manner that correlated with downregulation of KCC2
and heat-shock protein 72 (HS72). HS72 can exacerbate or
attenuate hypothalamic neuronal death depending on its
peptide expression levels and is not expressed in the mature
brain under standard conditions [44]. Parvalbumin positive
interneurons, which exhibit high SLC12A5 gene expression
and glutamatergic input, often survive these events even in
regions of complete pyramidal cell loss [45]. This suggests
that KCC2 expression is also mediated by brain health;
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Figure 3: Schematic representation of important regulatory phosphoresidues of the neuron-specific K–Cl cotransporter KCC2. The
mouse KCC2 co-transporter consists of 12 membrane spanning predicted segments, an N-linked glycosylated extracellular domain between
transmembrane domains 5 and 6. This is flanked by two cytoplasmic carboxy- and amino-terminal domains of 104 and 481 amino acids,
respectively. Positions of phosphoresidues that are critical for functional regulation of KCC2, including tyrosine 903 (Y903), threonine 906
(T906), serine 940 (S940), threonine 1006 (T1006, this site is corresponding to Rat T1007), tyrosine 1087 (Y1087), and S932 and T1008
(regulated byKCC2 activators staurosporine andN-ethylmalemide (NEM)), are indicated.ThePurple region denotes theKCC2 ‘ISO’ domain,
required for hyperpolarizing GABAergic transmission.
upregulation of the cotransporter may indicate onset or
previous infliction of neurological insult.
3. Neuronal Expression of KCC2
KCC2 is heavily expressed in the mature CNS and is rarely
found in peripheral neurons and nonneuronal cells [46–48].
Upregulation of KCC2 is correlated with neuronal differ-
entiation which occurs caudally to rostrally in the CNS
[49]. In the rodent CNS, the caudal section, i.e., spinal cord
and brain stem, shows little difference in KCC2 expression
compared to that observed in the more mature neuron [49–
51]. Conversely, rostral regions such as the hippocampus
and neocortex display upregulation of SLC12A5mRNA from
birth [49, 52].
Whilst KCC2 clearly displays region specificity within
the body, these studies fail to consider variation in the
cotransporter’s expression between species. In rats and mice,
for example, KCC2 levels remain low resulting in greater
𝐸GABA [12]. Data collected by Dzhala et al. (2005) showed
that a similar expression pattern was present in neonatal
humans. Human parietal lobe autopsy specimens displayed
high neuronal expression of NKCC1 and low expression of
KCC2 but only before the end of the first year of life [11].
Conversely, work conducted by Sedmak et al. (2016) noted
KCC2 expression begins much earlier in humans, during
the mid-foetal period and increases to levels resembling
adult maturity 6 months after birth [53]. Such inconsistencies
may be explained by the use of only a single brain region
in Dzhala’s study. Alternatively, differences in maturation
between humans and rodents may be responsible. Neonatal
rat and mice cortices, for example, achieve a developmental
stage which equates to the beginning of the third trimester
of gestation in the human foetus [54, 55]. Together, these
data indicate that KCC2 expression may be considered both
species- and age-dependant.
KCC2 protein expression has also been associated with
Ca2+-dependent mechanisms following neuronal damage
[56–58]. Various studies have shown that KCC2 activity is
heavily reduced after cleavage at the C-terminal domain by
calpain proteases. Hypoxic-ischaemic encephalopathy is con-
sidered a major contributor to long-term neuronal damage
with an apparent relationship between increased intracellular
Ca2+ and neuronal damage under hypoxic conditions [59].
Calpains are Ca2+-dependent proteases. Perinatal mammals
exhibit a high calpain/calpastatin (the inhibitor of calpain)
ratio. Calpain overexpression or excessive activity has been
associated with the symptoms of several neurological con-
ditions including hypoxic ischaemia [60, 61], seizures [57],
and epilepsy [62]. KCC2 upregulation is required during
neuronal maturation to enhance the inhibitory properties of
GABAAR [12, 21]. This process is, therefore, highly sensitive
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to excessive calpain activity causing a paucity of active KCC2.
Thus, calpains may play a fundamental role in the aetiology
of these diseases.
4. Regulation of KCC2 Activity
4.1. Phosphorylation. The activity and expression of KCC2
at the plasma membrane is regulated by phosphorylation.
KCC2’s carboxyl-domain is the target for several known
kinases and is regularly phosphorylated at the serine 940
(S940) residue. Phosphorylation of S940 decreases KCC2
internalisation maintaining high KCC2 membrane expres-
sion [63].This process is regulated by protein kinase C (PKC)
which directly phosphorylates S940 resulting in greater trans-
porter activity [63]. In contrast, dephosphorylation causes a
fall in KCC2 activity mediated by a reduction in transporter
stability [64]. The S940 residue and PKC activity are, there-
fore, key components in KCC2 regulation. Modulation of
PKC activity by separate pathways, therefore, also indirectly
regulates KCC2 activity and Cl− homeostasis. Of note is the
neuropeptide oxytocin which was found to increase KCC2
activity and support GABAergic signalling by Leonzino et al.
(2016) [65]. Using PKC-inhibitors, Leonzino and colleagues
prevented oxytocin mediated KCC2 upregulation suggesting
a regulatory role of the neuropeptide in this process [65].
The neurotransmitter serotonin has also been reported
to influence KCC2 activity. Serotonin binds and activates
the receptor 5-hydroxytryptamine type 2A (5-HT2A) in a
process that increases cell membrane KCC2 levels and subse-
quently restores endogenous synaptic inhibitory mechanisms
in mouse models displaying injury to the spinal cord [66].
This serotonin-mediated activity is believed to be PKC-
dependent given that PKC inhibitors reduced KCC2 activity
[66]. Together, these results suggest S940 phosphorylation is
influenced by several pathways. Given the crucial regulatory
role of this residue, we can infer that the transporter’s expres-
sion oscillates according to a variety of paracrine stimuli.
Given the increased cell-surface density of KCC2 during
S940 phosphorylation, this may be a particularly promising
area of therapeutic study. Therapeutic enhancers of S940
phosphorylation may prove effective in this field especially
given the recent finding that KCC2 potentiation can limit
onset and severity of neuropathic seizures [67].
The dependence on C-terminal domain integrity dis-
played by KCC2 makes this domain a potential target for
therapeutic treatments. For example, KCC2 membrane sta-
bility is heavily reduced when tyrosine residues 903 and 1087
are phosphorylated causing its subsequent trafficking to the
lysosome [64]. In addition, the threonine906 (Thr906) and
threonine1007 (Thr1007) residues display inhibitory character-
istics when phosphorylated [68, 69]. During the neonatal
period, brain localised Thr906 and Thr1007 are often phos-
phorylated, thereby preventing premature KCC2 activity [68,
69]. Mutants of KCC2, however, commonly show variation
at these phosphorylation residues. Mutations at S932 to
aspartate (S932D, mimicking phosphorylation) or T1008
to alanine (T1008A, mimicking dephosphorylation) signif-
icantly enhance KCC2 activity (up to 1.5-2-fold increase)
in HEK293 cells [70]. Mutation at S940 to alanine (S940A,
mimicking dephosphorylation) in vivo reduces KCC2 activity
and enhances the effects of kainate-induced status epilepticus
[36]. In contrast, Thr906A/Thr1007A double-point alanine
substitution enhances KCC2 function in cell culture [67,
68, 71, 72]. Interestingly, Thr1007A mutations do not impact
KCC2 surface expression. Preventing phosphorylation of
Thr906 and Thr1007 is, however, sufficient to enhance the Cl−
extrusive properties of KCC2 in vivo [67]. Such findings
suggest that this is not just the result of increased KCC2
protein but rather multiple processes. The authors hypoth-
esised that these mutations increase KCC2 affinity for Cl−.
KCC2 Thr906A/ Thr1007A variant-carrying neurons reached
Cl− equilibrium at a more negative E
𝐺𝐴𝐵𝐴
than the wild
type control. When Cl− admittance is low, the increased Cl−
affinity displayed by these variants aids extrusion at levels
beyond the wild-type threshold [67]. This increase in KCC2
function was sufficient to reduce chemoconvulsant-induced
seizure activity and severity [67], suggesting that the cotrans-
porter has therapeutic potential as a seizure limiting drug
target.
Recent data provided by Friedel et al. (2015) showed
the protein, With-no-lysine kinase 1 (WNK1) stimulated
phosphorylation of both Thr906 and Thr1007 by means of
the Kinase, Ste20-related proline alanine-rich kinase (SPAK)
[69]. SPAK was phosphorylated and subsequently activated
by WNK1 inhibiting KCC2 activity [69]. SPAK function and
phosphorylation may also fluctuate throughout development
depending onWNK1 activity [73]. Should phosphorylation of
KCC2 residues Thr906 and Thr1007 occur in immature brains
but fall during development, it may explain why KCC2-
dependent Cl− extrusion dominates in the adult CNS [69].
WNK1 is, therefore, a key regulator of KCC2 activity and
a potential therapeutic target for the treatment of excita-
tory/inhibitory disorders.
Interestingly, Friedel et al. (2015) also found that inhibi-
tion of WNK1 dephosphorylated KCC2 at Thr906 andThr1007
[69]. This relationship was noted in other studies suggesting
a regulatory role of WNK1 in KCC2 activity. KCC2 activity
assays showed the amino acid taurine significantly inhibited
KCC2 via serine/threonine phosphorylation compared to
control and also activated WNK1 [74]. This corroborates
Friedel et al. (2015) who showed that inhibition of WNK1
increased [Cl−]i extrusion in a KCC2-dependent manner in
cultured rat hippocampal and cortical neurons [69]. Genetic
studies examining changes in WNK1 activity may elucidate
the aetiology of many neurological diseases.
Using the organic compound N-ethylmaleimide (NEM),
Conway et al. (2017) increased KCC2 activity through
increased S940 phosphorylation and decreasedThr1007 phos-
phorylation [72]. Interestingly, NEM was found to potentiate
KCC2 activity in neurons, particularly in cells with higher
pThr1007 levels or lower pS940 [72]. Furthermore, KCC2
mutation S932D could abolish further stimulation by NEM,
whereas T1008A by another KCC2 activator, staurosporine
[70]. Such findings provide valuable insight into therapeutic
limitations as drugs that act to modulate KCC2 surface levels
or intrinsic conformational change through phosphorylation
[33, 34] would only be effective in cases of high pThr1007 or
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high pThr1008 and low pSer940 or low pSer932.These attributes
are more common in cases of spinal cord injury. Nevertheless
such drugsmay be of some use in the treatment of neurologi-
cal disorders. Despite this limitation, their work suggests that
manipulation of Thr1007 phosphorylation may prove relevant
to the advancement of neurological therapeutics.
An independent study identified the regulatory role of
five phosphosites Ser31, Thr34, Ser932 , Thr999, and Thr1008
using alanine and aspartine mutants [70]. Substitution of
Ser31, Thr34, and Thr999 did not affect KCC2 activity.
Ser932D (mimicking phosphorylation) and Thr1008A (mim-
icking dephosphorylation), however, increased transporter
activity [70]. In addition, treatment with the known KCC2
activators NEM or staurosporine was ineffective in activating
Ser31D, Thr34A, Ser932A/D, Thr999A, Thr1008A/D or Ser31A,
Thr31D, Ser932D KCC2 variants, respectively [70]. These
results demonstrated the existence of phosphosensitive sites
that regulate KCC2 activities via the integration of various
signalling pathways.
4.2. Trophic Factors. KCC2 activity ismodulated by a number
of trophic (growth) factors including TGF-𝛽2 [75], neu-
rotrophic factor [76], and brain-derived neurotrophic factor
(BDNF) [57]. Of these, BDNF is the most well-studied
modulator of KCC2 activation.
BDNF is a 27-kDa polypeptide involved in neuronal
survival, differentiation, and growth [77]. Its role in KCC2
regulation was first discovered by Aguado et al. (2003) who
noted that KCC2mRNA levels increased with overexpression
of the BDNF gene in developing neurons. This process was
later found to utilise the Tropomyosin-related kinase (Trk)
pathway, as deletion of the TrkB isoform decreased KCC2
mRNA [78].These data suggest a proregulatory role of BDNF
in immature neurons. In mature neurons, however, BDNF
downregulates KCC2 at both the protein and RNA levels
[79, 80].
Recently,Huang and colleagues notedBDNF-KCC2 regu-
lation was injury dependent. In intact animals, BDNF down-
regulated membrane-bound KCC2. In animals with spinal
cord injury, however, BDNF upregulated the cotransporter
[81]. Reasons for these differences are not yet understood,
although the authors suggested one hypothesis based on
BDNF-TrKB receptor binding.This causes activation of signal
pathway components such as PLC𝛾; BDNF downregulates
KCC2 in the presence of PLC𝛾 but upregulates it when PLC𝛾
is lacking. Given that spinal cord injury has previously been
found to decrease PLC𝛾 expression [80], it may play a logical
role in injury-dependent KCC2 regulation. Interestingly, a
separate study has shown that BDNF plays a crucial role
in KCC2 upregulation after seizure-induced neuronal insult
[57]. Together, these studies suggest that targeting BDNFmay
be of therapeutic value in the treatment of diseases involving
KCC2 downregulation.
4.3. Transcriptional and Translational Regulation. KCC2 ex-
pression is exclusive to neuronal cells, as dictated by the
activity of a neuron-restrictive silencing element (NRSE)
acting at the first intron of SLC12A5 [82, 83]. A 1.4 kb
promoter fragment is also implicated in KCC2 neuron
expression. This was identified in a transgenic model lacking
NRSE. Cells lacking NRSE showed increased levels of KCC2
expression and also expressed the active 1.4 kb promoter
fragment [39]. The transcription factor Erg4 has since been
found to bind to this promotor fragment and regulate KCC2
expression [40]. SLC12A5 also displays a second binding
site within its promoter region known as the E-box region,
which binds upstream stimulating factors (USF) 1 and 2.
USF1 is negatively regulated by amyloid precursor protein
(APP)which simultaneously downregulatesKCC2 [84].USF1
is, therefore, a potentially key component in the expression
pattern of KCC2. Regulatory proteins such as APP and
USF1 may act as biomarkers for the early identification of
neurological and epileptic disease.
For successful Cl− extrusion, KCC2 must be expressed
at the cell surface. A further role in which APP is impli-
cated is the stabilisation of KCC2 at the cell membrane.
Direct binding of APP to KCC2 blocks phosphorylation of
the tyrosine residues (903, 1087) which normally promote
transporter internalisation and degradation [85]. In this way,
APP acts as both a pre- and posttranslational regulator of
KCC2 activity and displays strong therapeutic potential for
the treatment and/or diagnosis of diseases associated with
KCC2 dysfunction.
Surface expression of the KCC2 cotransporter is regu-
lated by kainate receptors, through formation of molecular
complexes between the kainate receptor subunit GluK2 and
KCC2 [86, 87]. Phosphorylation of Gluk2 by PKC increases
KCC2 activity, but PKC can also act directly on the cotrans-
porter due to activation of group 1 metabotropic glutamate
receptors (mGluRs). Through induction of Ca2+ release
from internal stores, these receptors increase intracellular
levels of the cation [88]. PKC is a Ca2+-sensitive kinase
meaning its subsequent activation by group 1 mGluRs is
an important component of KCC2 recorded activity. In
this way, glutamatergic signalling can indirectly enhance
inhibitory GABAergic signalling through increased KCC2
activity [88]. This process is implicated in maintaining
equilibrium between excitatory and inhibitory signals [88].
Many neurological diseases are attributed to imbalance of
these signals. This indirect mechanism of KCC2 regulation,
therefore, presents a potential therapeutic pathway for drug
targeting.
5. The Role of KCC2 in the Development
of Epilepsy
The role of KCC2 mutants in epilepsy development was
discovered in two separate studies conducted on patients
displaying different epileptic symptoms. The first studied
an Australian family suffering from febrile seizures and
identified an arginine-to-histidine substitution at position
952.This missense mutation, formally named R952H, caused
a substantial decrease in KCC2 membrane expression com-
pared to the wild-type control [89]. The second, conducted
by Kahle and colleagues, investigated idiopathic generalised
epilepsy in a cohort of Canadian patients displaying the same
BioMed Research International 7
mutation, c.2855G>A (R952H) [90]. Companion studies
noted a significant decrease in Cl− extrusion compared to
control indicative of KCC2 impairment [90].
Kahle et al. (2014) also found a second KCC2 variant,
R1049C, with a cysteine substitution at the 1049 position.
According to in silico bioinformatics programmes, this
mutation is predicted to possess pathogenic properties that
correlate with KCC2 dysfunction [90]. In accordance with
the findings of Puskarjov et al. (2014), Kahle and colleagues
showed that R952H mutants had a significantly lower level
of KCC2 expressed at the cell surface. In R1049C mutants,
however, KCC2 levels were not noticeably different to control
[89, 90]. R1049C reduced KCC2 efficacy for Cl− extrusion,
resulting in higher basal [Cl−]i levels and membrane depo-
larisation at the previously inhibitory synapse [90]. Both
variants also displayed a significant (>50%) decrease in
S940 phosphorylation. Thus, both R952H and R1049C C-
terminal mutations reduce KCC2 activity. This, in part, may
be due to a decrease in stimulatory S940 phosphorylation
[90]. Alternatively, interaction of these variants with the ISO
domain (a unique 15 amino acid region on the KCC2 C-
terminal domain) which has previously been identified as
a vital component to KCC2 isotonic activity may cause the
observed reduction in KCC2 function [91].
More recently, Sto¨dberg and colleagues identified an
autosomal recessive heterozygous loss-of-function mutation
in the SLC12A5 gene in children from two separate families
[92]. In both families, two children developed clinical features
of epilepsy of infancy with migrating focal seizures (EIMFS).
All mutated residues were of KCC2b lineage: L288H, L403P,
and G528D. Of the four children examined, two had com-
pound heterozygous mutations, c.1208T>C (p.L403P) and
c.1583G>A (p.G528D), whilst the others had homozygous
missense mutations, c.863T>A (p.L288H) [92]. L403P and
G528D mutants displayed complete loss of KCC2-mediated
Cl− extrusion, whilst the homozygous L403P mutant had
reduced surface expression and glycosylation leading to
partial loss of function [92]. Their data further contributes
to the growing evidence that disruption of KCC2 activity is
implicated in epilepsy. Research into additional mutations
affecting SLC12A5 may provide novel insight into the indi-
vidual application of antiepileptic strategies.
There are, however, limitations to the data collected
here that cannot be overlooked. All variants described in
these studies were only identified through examination of
the SLC12A5 gene sequence. The need for whole genome
sequencing intervention to identify other variants or alleles
not encoded by SLC12A5 but that augment KCC2 activity was
raised by these studies [89, 90, 92].
Another study conducted by Saitsu et al. (2016) also
identified four previously undiscovered KCC2 variants that
resulted in EIMFS [93]. In a sample of ten sporadic and one
familial case of EIMFS, whole exome sequencing identified
compound heterozygous SLC12A5 variants in two families:
c.279+ 1G >C causing skipping of exon 3 in the tran-
script (p.E50 Q93del), c.572C>T (p.A191V) in two siblings,
and c.967T>C (p.S323P) and c.1243 A>G (p.M415V) in
another individual. Another patient with migrating multi-
focal seizures carrying compound heterozygous mutations,
c.953G>C (p.W318S) and c.2242 2244delTCC (p.S748del),
was also identified fromwhole exome sequencing data of 526
patients and targeting of the SLC12A5 sequence from a cohort
of 141 patients with infantile epilepsy [93]. Gramicidin-
perforated patch-clamp analysis identified a reduction in Cl−
extrusion of E50 Q93del and M415V mutants, with mildly
impaired function of A191V and S323P mutants. Membrane
expression of these KCC2 variants did not differ from control.
Heterologous expression of two KCC2 variants, however,
mimicking the patients’ status, showed significantly higher
[Cl−]i levels than wild-type KCC2 but lower levels compared
to the group lacking KCC2 [93]. These findings indicate that
even partial disruption to neuronal Cl− extrusion, mediated
by two impaired variants of SLC12A5, causes EIMFS.
Since these discoveries, gene panel sequencing of an
EIMFS patient from an unrelated family found a com-
pound heterozygous constellation of variants in SLC12A5
consisting of a maternally inherited p.Ser399Leu and a de
novo p.Arg880Leu mutation in human KCC2b [93]. Such
mutations may be pathogenic.
6. KCC2 in Neurodevelopmental Disorders
KCC2’s C-terminal domain is encoded at the 3’ end of the
SLC12A5 gene [90]. Recently, Merner et al. (2015) investigated
KCC2 regulatory variation using Sanger sequencing to inves-
tigate the coding nucleotides 21-25 of the SLC12A5 gene [94].
The authors screened a total of 427 autism spectrum disorder
(ASD), 143 schizophrenic, and 190 intellectual disability cases
[94]. R952H and R1049C were among the mutations found
in ASD cases. Interestingly, R952H was also implicated in
schizophrenia, suggesting overlap between these disorders.
Different phenotypic outcomes from R952H mutation (i.e.,
which disease the patient has) are likely dependent on other
allele interactions.
Thorough understanding of how risk alleles contribute
to disease is not yet established. In polygenic disease mod-
els, causality is never attributed to just one variant [95].
Merner showed that patients with ASD carried rare KCC2
variants that affected CpG sites [94]. CpG sites are prone to
methylation, a process that can alter the expression pattern
of the gene [96]. Variation in SLC12A5 expression in patients
with ASD may, therefore, be the consequence of epigenetic
interactions, which represent a potentially valuable focus for
future research.
7. KCC2 in Neuropathic Pain
Neuropathic pain (NP) is characterised by spontaneous pain
sensations and tactile allodynia. The system of pain detection
requires a balance of excitatory and inhibitory signals. When
this balance is disrupted either through injury or psychogenic
insult, it can lead to NP. In both the spinal cord and
dorsal horn, synaptic transmission patterns vary between
NP models [97, 98]. This pain has been attributed to dys-
functional inhibitory mechanisms in the spinal cord. In fact,
pharmacological disruption of synaptic inhibition within the
dorsal horn induces symptoms commonly attributed to NP
[99]. Reduction of the Cl− gradient across the neuronal
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membrane has since been identified as the cause of NP
initiated by peripheral nerve injury [100].This is the result of
downregulation of KCC2. During NP pathogenesis, an array
of cellularmechanisms converge causing a reduction inKCC2
expression and function and increase in neuronal [Cl−]i
[100]. The need to identify cellular mechanisms that increase
KCC2 activity during neuropathic episodes is, therefore,
crucial to the advancement of therapeutics in this field.
Increasing KCC2 activity presents a very prudent area of
research [101–103]; the ability to restore normal inhibitory
function in neurological conditions associated with impaired
Cl− transport may prove to be an effective therapeutic strat-
egy. High-throughput screening assays have now identified
KCC2 activators that reduce [Cl−]i. Gagnon et al. (2013) opti-
mised a first-in-class arylmethylidine family of compounds
(CLP257) to lower [Cl−]i [104]. CLP257 rescued KCC2
plasma expression, renormalised stimulated recall responses
in spinal nociceptive pathways sensitized after nerve injury,
and reduced hypersensitivity of NP rat models [104]. The
results of Cardarelli et al. (2017), displaying CLP257 as a
direct KCC2 activator, were not replicable [105] but do reveal
the compounds’ ability to potentiate GABAAR activity [105].
Furthermore, GABAAR-dependent synaptic inhibition by
KCC2 antagonist, gabazine could actually tune KCC2 activity
via the Cl−-sensitive WNK1 kinase [106]. Oral treatment of
the CLP257 prodrug equivalent, CLP290, showed similar
efficacy to their control of pregabalin, a drug commonly
used in the treatment of epilepsy and anxiety [104, 107]. Side
effects of pregabalin include dizziness and sedation causing
motor function disturbance [107]. Such side effects were not
present during treatment with CLP290 [104]. These results
highlight KCC2 as a plausible target for NP drug therapy
and may provide further insight into the treatment of other
neurological disorders.
8. Therapeutic Potential of KCC2
KCC2’s interaction with Cl− importer GABAAR makes it
a potential target for the treatment of several neurological
diseases. Currently, phenobarbital (PB), a barbiturate that
delays the closing of GABAAR, is the most common first-
line drug used for the treatment of seizures [108]. Hypoxic-
ischaemic encephalopathy is a major contributor to the onset
of neonatal seizures, with over 50% of patients displaying
electrographic seizures even after treatment with PB [109].
Interruption to the expression and/or function of either
KCC2 or NKCC1 affects the antiseizure efficacy of GABAAR
agonists [110]. The higher [Cl−]i within immature neurons
potentially contributes to resistance to pharmacological first-
line antiseizure GABAAR agonists in the immature brain
[111].
Recently, a translational model for age-dependent PB-
resistant seizures was developed by Kang et al. (2015)
[112]. Using a permanent unilateral carotid-ligation model
of neonatal ischaemic-seizures in CD-1 pups, the authors
investigated the ability of the NKCC1 antagonist bumetanide
to rescue PB-resistance. Bumetanide failed to rescue PB as
an antiseizure therapeutic [112]. A number of preclinical
models show that the severity of seizure and mechanism of
damage can influence the efficacy of antiseizure drugs and
alter cotransporter expression [113–116]. Kharod et al. (2018)
noted model-specific insults modulated both expression and
function of the NKCC1 and KCC2 cotransporters. Using a
pentylenetetrazol-induced seizure model, they identified a
significant upregulation of KCC2. In contrast, ischaemia-
induced seizures significantly downregulated KCC2 [117].
These data combined reveal KCC2 expression to be insult
specific and may explain why some anticonvulsant therapies
display variable efficacy during first-line treatment.
Activation of the Trk isoform TrkB has been shown
to induce phosphorylation of phospholipase C-𝛾1 which is
linked to the downregulation of KCC2 and development of
epilepsy [118, 119]. Carter et al. (2018) showed that TrkB
antagonist, ANA12, increases the efficacy of PB inCD1mice at
doses as low as 2.5mg/kg. ANA12 also rescued KCC2 expres-
sion after postnatal ischaemia [120]. Unlike current clinical
antagonists (e.g. bumetanide, furosemide), ANA12 is capable
of passing through the blood-brain-barrier [121], allowing it
to have greater therapeutic impact on KCC2 activity as this
has previously been a limiting factor for treatments [122].
ANA12may, therefore, have therapeutic benefit by preventing
downregulation of KCC2, thus maintaining low [Cl−]i.
9. Conclusion
KCC2 is a key player in the maintenance of neuronal Cl−
homeostasis. A plethora of studies identifyKCC2dysfunction
and misregulation as a key component in the development
and onset of many neurological diseases. KCC2 is a strong
candidate for therapeutic targeting and should be further
considered by pharmaceutical investors. It should be noted
that the majority of these findings are not made in human
neuronal cell lines and are, therefore, limited in their ability to
determine the immediate effects of targeting KCC2. Despite
this, the data collected from human participants indicates
that there is a place for KCC2 pharmaceuticals in the treat-
ment of epilepsy. Continued research in human neuronal cell
types may reveal more opportunities for drug development.
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